NCT03651947View on ClinicalTrials.gov

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

November 17, 2018

Study Completion Date

May 22, 2019

Conditions
Healthy People
Interventions
DRUG

QL1206

subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.

DRUG

Xgeva®

subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.

Trial Locations (1)

130000

The First Affiliated Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT03651947 - Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults | Biotech Hunter | Biotech Hunter